Company: XAIR
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001641172-25-023243
Chunk: 33

Company: Beyond Air, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
 

The
Company determined that the fair value per share of NeuroNos’ common stock to be $3.00 at the grant date during the three months
ended June 30, 2025 based on the valuation of common stock purchased by external investors during March 2025.

The
following summarizes the components of stock-based compensation expense which included stock options and restricted stock units for the
three months ended June 30, 2025 and June 30, 2024:

 SCHEDULE
OF STOCK-BASED COMPENSATION EXPENSE 

    2025  
    2024 

    Three Months Ended 
  
    (in thousands) 
    June 30, 

    2025  
    2024 

    Research and development 
    $300  
    $629 
  
    General and administrative 
     1,277  
     2,750 
  
    Total stock-based compensation expense 
    $1,577  
    $3,379 

Warrants

A
summary of the Company’s outstanding warrants as of June 30, 2025 is as follows:

 SUMMARY
OF COMPANY’S OUTSTANDING WARRANTS 

    Warrant Holders 
    Number of Warrants  
    Exercise Price  
    Intrinsic Value (in thousands)  
    Date of Expiration

    NitricGen agreement 
     4,000  
    $138.00  
     -  
    January 2028
  
    Avenue agreement 
     11,693  
    $7.59  
     -  
    June 2028
  
    March 2024 raise 
     481,936  
    $45.00  
     -  
    March 2027
  
    Avenue extension agreement 
     5,000  
    $25.60  
     -  
    June 2029
  
    September 2024 equity offering 
     1,994,360  
    $7.59  
     -  
    September 2029
  
    September 2024 debt instrument 
     757,977  
    $7.59  
     -  
    September 2029
  
    Sub-total 
     3,254,966  
    $13.31  
    $-  

    Pre-funded warrants 
     606,367